Newsroom



News

PHCentral News is gathered daily to bring you the latest developments in pulmonary hypertension treatments and research as well as stories we think are useful on an array of topics.  Under current news, you will find a dynamic list of stories for the last thirty (30) days.  You will find older news stories in our archives.    Stories about specific treatments can also be found in the medical section.

If you run across a PH news story we've missed or important story with broad appeal, please send us the link and we'll make sure it gets added.   Send news:  contact/info+phcentral+org.



  • December 20, 2014
  • The PHC news team - Ralf, Helen, Paul and Cheryl - is taking a short break over the Christmas and New Year Holidays.  We'll be back in action in 2015.  The happiest of holidays to all of you.  Be well.
  •   
  • December 19, 2014
  • The ocular impact of Sildenafil
  • (Opticianonline.net) Sildenafil, sold as viagra for ED or revatio for pulmonary arterial hypertension can cause an eye disease called NAION..
    click headline for more

  •   
  • First results of Russia's national PH registry
  • (PubMed) The formation of a national register of patients with PH and CTEPH makes it possible to introduce current approaches to diagnosing and treating the patients of this category and to evaluate the efficiency and quality of rendered medical care and will contribute to the estimation of required health care volumes and the expenditure of public health resources...
  •   
  • Cytori Announces Informational Session on Potential Therapy for Scleroderma
  • (Pulmonary Hypertension News) Late-stage cell therapy company Cytori Therapeutics, Inc. will host an informational session about its pivotal STAR clinical trial, which aims to expand knowledge about scleroderma and test a potential treatment for the disease. The company, which is currently developing autologous cell therapies from adipose tissue, will use the information session on January 14, 2015, from 1:30 PM to 4:30 PM at the Prescott Hotel, 545 Post Street, San Francisco, Room 736, to provide more information about their current progress in treating scleroderma.
  •   
  • December 18, 2014
  • Interleukin 13– and interleukin 17A–induced pulmonary hypertension phenotype due to inhalation of antigen and fine particles from air pollution
  • (Jstor.org) A new study points to IL-13- and IL-17A-coinduced inflammation as a new template for biomarkers and therapeutic targeting for the management of immune response–induced pulmonary hypertension. When IL-13 and IL-17A were downregulated by antibodies in animal trial, pulmonary hypertension improved. 


  •   
  • December 17, 2014
  • A bunch of exciting free fulltext PH-aticles from PVRI
  • (JStor.org) click headline to read more
  •   
  • The first annual Drug Discovery and Development Symposium for Pulmonary Hypertension
  • (JStor.org) New approaches to PH are emerging from basic studies of signaling, management of the genome, and preservation of metabolic function and from testing of newer molecules that have efficacy in oncologic and inflammatory illnesses.
    [..]
    A "must read" article for interested PH patients, click headline
  •   
  • Acute hemodynamic response of infused fasudil in patients with pulmonary arterial hypertension: A randomized, controlled, crossover study.
  • (PubMed) Infused fasudil improved pulmonary hemodynamics in patients with PAH without significant toxicity.
  •   
  • December 16, 2014
  • GlaxoSmithKline seeks expanded hypertension approval for Volibris
  • (Zenopa) A regulatory submission has been filed with the European Medicines Agency for a variation to the marketing authorisation for Volibris, allowing it to be used in initial combination therapy for patients with pulmonary arterial hypertension.
  •   
  • The Year in Medicine 2014: News That Made a Difference
  • (Medscape) A presentation about medicine highlights in 2014
  •   
  • A predictive model of the effects of depression, anxiety, stress, 6-minute-walk distance, and social support on health-related quality of life in an adult pulmonary hypertension population.
  • (Pubmed) The findings indicate depression, anxiety, stress, 6-minute walk distance, and social support play important roles in HRQOL among patients with PH. Advanced practice nursing strategies to increase HRQOL include counseling, psychiatric referrals, psychotherapy, guided imagery, leading support groups, and low-grade resistance training.
  •   
  • December 15, 2014
  • GSK Seeks European Approval for Ambrisentan as PAH Combination Therapy
  • (Pulmonary Hypertension News) GlaxoSmithKline (GSK) recently announced it has applied for a European Medicines Agency (EMA) variation to the Marketing Authorization for ambrisentan (Volibris®), in order to expand the currently approved indication to include its use as a first-line combination therapy with tadalafil for pulmonary arterial hypertension (PAH). Ambrisentan is classified as a selective endothelin type-A receptor antagonist, which was previously approved in the European Union (EU) as a treatment for PAH classified as WHO functional class II and III to enhance tolerance for physical activity.
  •   
  • December 13, 2014
  • Silence Therapeutics To Utilize New Genetic Toolkit For PAH Drug Development
  • (Pulmonary Hypertension News) Silence Therapeutics recently developed a genetic toolkit to support the company’s research into to several diseases, including pulmonary arterial hypertension (PAH).
  •   
  • December 12, 2014
  • FDA Postmarket Trial for PAH Treatment Bosentan Reveals Drug Does Not Reduce Time To Mortality Rates
  • (PHNews) Drug maker Actelion has indicated that the company’s Food and Drug Administration (FDA)–approved pulmonary arterial hypertension (PAH) drug Bosentan, which is also known under the brand names of Actelion and Tracleer, recently failed a key FDA postmarket test. The test, which was part of the postmarket COMPASS 2 trial, revealed that Bosentan did not reduce time to first morbidity or mortality compared with a placebo.
  •   
  • December 11, 2014
  • Actelion European MAA for PAH Drug Selexipag Pending Approval
  • (PHNews) Actelion Pharmaceuticals Ltd., has just announced its has sent the European Medicines Agency (EMA) an application for the centralized Marketing Authorization of selexipag (Uptravi®), indicated for the treatment of pulmonary arterial hypertension (PAH). While the drug’s MAA is pending validation, the company is working on submissions to the US Food and Drug Administration and other regulatory agencies across the globe.
    ...
    According to a report published June 2014, Selexipag reduced the risk of morbidity/mortality in PAH patients by 39 percent, compared to those who received a placebo. Treatment response was consistent across patient subgroups (age, gender, WHO Functional Class, PAH etiology and background PAH therapy) treated for up to 4.2 years.
  •   
  • December 10, 2014
  • STAT5a/b Gene May Be Responsible for Gender Differences in Pulmonary Hypertension
  • (PHNews) A research group has found a gene that may control pulmonary hypertension severity, as well as the less severe form that occurs in women versus men.
    ...
    The STAT a/b gene may control the severity of pulmonary hypertension and could be controlled by estrogen levels. This could explain why women do not get as severe pulmonary hypertension as men.
  •   
  • December 9, 2014
  • New Clinical Trial Tests Ambrisentan in Preventing SSc-PAH
  • (PHNews) Treating patients with systemic sclerosis (SSc) who have borderline pulmonary arterial hypertension (PAH) is vital to patient health...The trial focuses on treating SSc patients 18 years and older with ambrisentan in a phase 2 proof-of-concept, efficacy and safety clinical trial.
  •   
  • December 8, 2014
  • Researchers Uncover New Insights Into Vascular Receptor Autoantibodies in PAH Associated with SSc
  • (PHNews) A new study, entitled “Vascular Receptor Autoantibodies in Pulmonary Arterial Hypertension Associated with Systemic Sclerosis,” reveals that antibodies against endothelin receptor type A (ETAR) and angiotensin receptor type-1 (AT1R) are involved in Systemic sclerosis (SSc)-associated pulmonary arterial hypertension (PAH) pathogenesis.
  •   
  • December 7, 2014
  • Noninvasive PAH diagnosis on the horizon
  • (Medwire News) Measuring the duration of vortical blood flow in the main pulmonary artery allows accurate estimation of pulmonary blood pressure and diagnosis of pulmonary arterial hypertension (PAH), say researchers.
  •   
  • New Clinical Trial Tests Ambrisentan in Preventing SSc-PAH
  • (Pulmonary Hypertension News) Treating patients with systemic sclerosis (SSc) who have borderline pulmonary arterial hypertension (PAH) is vital to patient health, as life expectancy after a diagnosis of SSc-PAH is only one year. Accordingly, Heidelberg University, along with GlaxoSmithKline, initiated a clinical trial to investigate “Early Treatment of Borderline Pulmonary Arterial Hypertension Associated with Systemic Sclerosis (SSc-APAH) (EDITA).”
  •   
  • Eight Parameters Recommended to Monitor for PH in JSSc Patients
  • (Pulmonary Hypertension News) When young patients develop juvenile systemic sclerosis (JSSc), it is vital to monitor them for changes in cardiopulmonary parameters that may lead to conditions such as pulmonary hypertension. However, there are no current guidelines that describe which cardiopulmonary parameters are most vital to monitor in order to screen for diseases and begin necessary treatments. Dr. Ivan Foeldvari, as part of an international, collaborative research effort, spearheaded this concern by developing recommended screening parameters for monitoring patients with JSSc and presenting his findings at the 2014 American College of Rheumatology Meeting.
  •   
  • December 6, 2014
  • The Flavonoid Quercetin Reverses Pulmonary Hypertension in Rats
  • (Plos One) Quercetin is a dietary flavonoid which exerts vasodilator, antiplatelet and antiproliferative effects and reduces blood pressure, oxidative status and end-organ damage in humans and animal models of systemic hypertension. We hypothesized that oral quercetin treatment might be protective in a rat model of pulmonary arterial hypertension.
  •   
  • Researchers Discover Protein That Can Prevent Pulmonary Hypertension-Related Heart Failure
  • (Pulmonary Hypertension News) RegeneRx Biopharmaceuticals, Inc. announced a recent study where company’s scientists demonstrated that Thymosin beta 4 (TB4) can reduce or even prevent heart failure in a pulmonary hypertension mouse model. The study, entitled “Thymosin Beta 4 protects mice from monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy,” was published in the journal Plos One.
  •   
  • December 5, 2014
  • Prevalence, Determinants, and Prognostic Significance of Pulmonary Hypertension in Elderly Patients Admitted with Acute Decompensated Heart Failure: A Report from the BIO-HF Registry.
  • (Echocardiography) PHT was found in 280/401 patients (69%), including in 67% of patients with HF with reduced ejection fraction (HFrEF) and 73% of patients with HF with preserved ejection fraction (HFpEF) (P = 0.19). Clinical characteristics and comorbidities were similar between patients with and without PHT. The prevalence of PHT increased with increasing severity of mitral regurgitation (MR) (mild: 65%; moderate: 67%; severe: 85%; P < 0.01)...
  •   
  • December 4, 2014
  • Gene assosiated with gender differences in experimental PAH in mice fould
  • (PubMed) ..Studies of SMC and endothelial cell (EC) lines derived from vessels isolated from lungs of male and female IPAH patients and controls, revealed instances of coordinate reductions in STAT5a, STAT5b and ATL3 in IPAH-derived cells, including in SMCs and ECs from the same patient. Taken together, these data provide the first definitive evidence for a contribution of STAT5a/b to the sex-bias in PH in the hypoxic mouse, and implicate reduced STAT5 in the pathogenesis of the human disease.
  •   
  • December 3, 2014
  • CYP2C9 gene associated with bosentan-induced liver injury
  • (healio.com) “We conclude that patients carrying the variants CYP2C9*2 and CYP2C9*3 of the CYP2C9 gene are exposed to a significantly higher risk of liver toxicity during treatment with bosentan,” the researchers wrote. “Our results suggest that the examination of CYP2C9 variants in patients with [pulmonary hypertension] may increase safety and efficacy of drug therapy with bosentan. Thus, the systematic investigation of the genetic background of bosentan metabolism represents an important step in the direction of individualized therapy for [pulmonary hypertension].”
  •   
  • Ellagic acid prevents monocrotaline-induced pulmonary artery hypertension via inhibiting NLRP3 inflammasome activation in rats.
  • (International Journal of Cardiology) Ellagic acid ameliorates monocrotaline-induced pulmonary artery hypertension via exerting its anti-oxidative property inhibiting NLRP3 inflammasome signal pathway in rats.
  •   
  • December 2, 2014
  • PH Diagnosis, Treatment Aided By New Right Ventricle 4D RV-Function Imaging Systems
  • (Lung Disease News) Munich, Germany based TomTec Imaging Systems GmbH’s 4D RV-Function software has been developed to give clinicians a comprehensive evaluation of the right ventricle including volumes and strain analysis. Because pulmonary hypertension often impacts the right ventricle in both adult and pediatric cardiology, the launch of TomTec’s new technology gives medical practitioners valuable, new diagnostic and prognostic tools 
  •   
  • December 1, 2014
  • ACTELION SUBMITS SELEXIPAG (UPTRAVI) FOR EMA MARKETING AUTHORISATION IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
  • (Actelion Inc.) ALLSCHWIL, SWITZERLAND - 02 December 2014 - Actelion Ltd (SIX: ATLN) today announced the submission of a centralized Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for selexipag (Uptravi®) in the treatment of pulmonary arterial hypertension (PAH). The application is now pending validation. Submissions to the US Food and Drug Administration and other territories are forthcoming..
  •   
  • ACTELION SUBMITS SELEXIPAG (UPTRAVI) FOR EMA MARKETING AUTHORISATION IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
  • (Actelion Inc.) ALLSCHWIL, SWITZERLAND - 02 December 2014 - Actelion Ltd (SIX: ATLN) today announced the submission of a centralized Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for selexipag (Uptravi®) in the treatment of pulmonary arterial hypertension (PAH). The application is now pending validation. Submissions to the US Food and Drug Administration and other territories are forthcoming..
  •   
  • To be able to design goal-oriented treatment strategies in paediatric pulmonary arterial hypertension (PAH), we aimed to identify treatment goals by investigating the prognostic value of treatment-induced changes in noninvasive predictors of transplant-free survival.

    From the identified set of baseline predictors, the variables World Health Organization functional class (WHO-FC), N-terminal pro-brain natriuretic peptide (NT-proBNP) and tricuspid annular plane systolic excursion (TAPSE) were identified as follow-up predictors in which treatment-induced changes were associated with survival. Patients in whom these variables improved after treatment showed better survival (p<0.002).

    Therefore, WHO-FC, NT-proBNP and TAPSE are not only predictors of transplant-free survival in paediatric PAH but can also be used as treatment goals, as treatment-induced improvements in these variables are associated with improved survival. The identification of these variables allows for the introduction of goal-oriented treatment strategies in paediatric PAH.
  •   
  • November 30, 2014
  • Patients With Reactive Pulmonary Hypertension Present Higher Mortality Risk
  • (Pulmonary Hypertension News) Pulmonary hypertension (PH) is uniformly defined as high pressure in the pulmonary vasculature but can be divided into three groups: active, passive, and reactive. According to the Department of Anaesthesia & Intensive Care of Chinese University of Hong Kong, passive PH is due to high pressure in post-pulmonary capillaries, active PH is due to obstructions in capillary and precapillary vessels, and reactive PH is due somewhat to an active-superimposed-on-passive component.
  •   
  • Boehringer Ingelheim’s Nintedanib for IPF Receives Positive Opinion
  • (Pulmonary Hypertension News) Boehringer Ingelheim, a leader in the pharmaceuticals industry, recently received a positive opinion from the Committee for Medicinal  Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the use of nintedanib (suggested brand name OFEV®) in patients with idiopathic pulmonary fibrosis (IPF). Nintedanib is now on the fast track for approval by the EMA, as it has been granted accelerated assessment.
  •   
  • Proteomics of pulmonary hypertension: could personalized profiles lead to personalized medicine?
  • (PubMed) Pulmonary hypertension (PH) is a fatal syndrome that arises from a multifactorial and complex background, is characterized by increased pulmonary vascular resistance and right heart afterload, and often leads to cor pulmonale. Over the past decades, remarkable progress has been made in reducing patient symptoms and delaying the progression of the disease. Unfortunately, PH remains a disease with no cure. The substantial heterogeneity of PH continues to be a major limitation to the development of newer and more efficacious therapies. New advances in our understanding of the biological pathways leading to such a complex pathogenesis will require the identification of the important proteins and protein networks that differ between a healthy lung (or right ventricle) and a remodeled lung in an individual with PH. In this article, we present the case for the increased use of proteomics-the study of proteins and protein networks- as a discovery tool for key proteins and protein networks operational in the PH lung. We review recent applications of proteomics in PH, and summarize the biological pathways identified. Finally, we attempt to presage what the future will bring with regard to proteomics in PH and offer our perspectives on the prospects of developing personalized proteomics and custom-tailored therapies.
  •   
  • November 29, 2014
  • Surgical Cure for CTEPH Available in Vanderbilt Medical Center
  • (Pulmonary Hypertension News) A number of patients who were suffering from a type of pulmonary hypertension known as CTEPH, or chronic thromboembolic pulmonary hypertension, have gotten their normal life back after undergoing a breakthrough operation at the Vanderbilt Heart & Vascular Institute (VHVI). CTEPH develops in a small percentage of people who have a history of pulmonary embolisms, and without proper treatment, can lead to heart failure. Today’s CTEPH treatment options are few, but the VHVI is offering a highly effective surgical way to address the obstructive blood clots, and this information comes in light of the first ever CTEPH Awareness Day, observed November 18.
  •   
  • Pentraxin3 in Chronic Thromboembolic Pulmonary Hypertension: A New Biomarker for Screening from Remitted Pulmonary Thromboembolism
  • (Plos One) Pentraxin3 (PTX3) is a protein, which has multifaceted effects on innate immunity, angiogenesis, and vascular remodeling then could be a disease marker of acute myocardial infarction, heart failure, vasculitis. In addition, PTX3 has been recognized as a biomarker for pulmonary arterial hypertension, however whether it is the case in chronic thromboembolic pulmonary hypertension (CTEPH) remains unclear. Therefore, we investigated whether PTX3 would be a useful biomarker for detecting CTEPH with respect to differentiation from stable pulmonary thromboembolism (PTE), in comparison to other biomarkers.
  •   
  • miR-29a-3p Attenuates Hypoxic Pulmonary Hypertension by Inhibiting Pulmonary Adventitial Fibroblast Activation
  • (AHA Journals) Activation of pulmonary adventitial fibroblasts plays a key role in the pulmonary vascular remodeling in hypoxic pulmonary hypertension. Previous studies showed that miRNAs participated in the regulation of fibroblast activation. This study explored the role of miR-29 in the activation of pulmonary adventitial fibroblasts and the therapeutic potential in hypoxic pulmonary hypertension.
  •   
  • November 28, 2014
  • Why drying washing indoors can pose a serious health threat
  • (Journalism.co (UK)) As winter approaches, doctors are warning that wet washing dried indoors can pose a serious health threat for people with weakened immune systems or severe asthma 
  •   
  • November 27, 2014
  • Arena Pharma granted patent for pulmonary hypertension drug
  • (San Diego Source) Arena Pharmaceuticals Inc. (Nasdaq: ARNA) has been granted a new patent for its ralinepag drug for use in the treatment of such diseases as pulmonary arterial hypertension (PAH).
  •   
  • November 26, 2014
  • SSc-PAH Patients Demonstrate Endothelial-to-Mesenchymal Transition
  • (Pulmonary Hypertension News) It is widely accepted that hypertrophic mesenchymal stem cells contribute to pulmonary arterial hypertension (PAH) in individuals with systemic sclerosis (SSc). Now, as a result of a study presented at the 2014 American College of Rheumatology Meeting, scientists have reason to believe that endothelial cells can increase the pool of mesenchymal cells and further contribute to SSc-PAH.
  •   
  • November 25, 2014
  • Researchers Report Thymosin Beta 4 is Cardioprotective in Pulmonary Hypertension/Heart Failure Model
  • (PipeLine Review (press release)) RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx") today reported new published data demonstrating that Thymosin beta 4 (TB4) can be used effectively to prevent or reduce heart failure. In a standard murine model of pulmonary hypertension (induced by a toxic plant alkaloid) that causes compensatory right heart hypertrophy, TB4 significantly reduced the systolic pressure and right ventricular hypertrophy when compared to animals that were not treated with TB4. This study was reported in the scientific journal PLOS ONE, 
  •   
  • November 24, 2014
  • Long-term Benefit With Stem-Cell Transplant in Scleroderma
  • (MedPage Today) Patients with rapidly progressing systemic sclerosis (SSc) showed sustained benefits over 5 years after autologous hematopoietic stem-cell transplantation (HSCT), compared with nontransplanted patients, researchers reported here.
  •   
  • November 23, 2014
  • New Pulmonary Fibrosis Diagnostic Tool Would Be Faster & Quicker
  • (Pulmonary Hypertension News) A new study highlighting a diagnostic test based on peripheral blood for idiopathic pulmonary fibrosis entitled “Familial and sporadic idiopathic pulmonary fibrosis: making the diagnosis from peripheral blood” was recently published in BMC Genomics by Eric B Meltzer at Vanderbilt University Medical Center. In this study, the research team validated the diagnosis of sporadic idiopathic pulmonary fibrosis from peripheral blood samples by identifying a functional genetic signature. This new data may improve the diagnosis of idiopathic pulmonary fibrosis, making it quicker and easier.
  •   
  • Lung Transplantation Decisions For Scleroderma Patients Should Be Rethought, Study Says
  • (Pulmonary Hypertension News) New research presented at the American College of Rheumatology’s Annual Meeting in Boston claims that end-stage lung disease patients with diseases like Scleroderma should not be denied the opportunity of receiving a lung transplant because of extra-pulmonary factors and, consequently, short- and long-term survival concerns. The study comes from Researchers at Columbia University College of Physicians and Surgeons in New York City.
  •   
  • November 22, 2014
  • An IPF Game-Changer: A Primer on the Newly Approved Drugs
  • (Medscape) In October, the US Food and Drug Administration (FDA) approved two new drugs, nintedanib (Ofev®, Boehringer Ingelheim) and pirfenidone (Esbriet®, InterMune), to help manage this condition. Medscape Advisory Board member for Pulmonary Medicine, Steven Nathan, MD, was a principal investigator in studies on pirfenidone and nintedanib.

    Dr Nathan recently spoke to Medscape about the importance of the new drug approvals, how the drugs work, and how physicians might use them to potentially extend the lives of their patients.
  •   
  • UC San Diego Health System Launches First US CTEPH Registry
  • (Pulmnonary Hypertension News) The University of California San Diego Health System, a leader in chronic thromboembolic pulmonary hypertension (CTEPH) research and patient care, has just received a generous grant to fund the recent launch of the country’s first CTEPH registry. The $7.6 million grant comes from pharmaceutical giant Bayer HealthCare in time for the November Pulmonary Hypertension Awareness Month. UC San Diego Health System is also known for being the first to offer pulmonary thromboendarterectomy (PTE), a life-saving, curative procedure for CTEPH, which is currently available in less than 10 facilities nationwide.
  •   
  • November 21, 2014
  • Pulmonary Arterial Hypertension: A Better Understanding of the Three New Drug Therapies
  • (MedScape) Interview with Dr Nathan where the three new meds. are explained and compared.

    Medscape: I understand that three new drugs to treat PAH have been approved in the past year or two.
    Dr Nathan: Yes, indeed. The three drugs are riociguat (Adempas®), which acts on the nitric oxide pathway and further downstream as a direct guanylate cyclase stimulator, as well as sensitizing the receptor to endogenous nitric oxide. The second is an endothelin receptor antagonist (ERA) called macitentan (Opsumit®). The third is oral treprostinil, marketed as Orenitram™, which is the same compound as the treprostinil that is now used for intravenous, subcutaneous, or inhaled administration.....
    ---
    Medscape: Where do you think the menu of treatments for PAH is going?
    Dr Nathan: Thankfully, despite the availability of many treatment options, there's growing interest in developing new drugs. There are a number of agents in development beyond the currently available drugs, which mainly address the balance between vasodilation and vasoconstriction. These investigational therapies include antiproliferative agents, aimed at the root cause of PAH, with the potential of being more potent disease modifiers.
  •   
  • Patients With Reactive Pulmonary Hypertension Present Higher Mortality Risk
  • (Pulmonary Hypertension News) Pulmonary hypertension (PH) is uniformly defined as high pressure in the pulmonary vasculature but can be divided into three groups: active, passive, and reactive. According to the Department of Anaesthesia & Intensive Care of Chinese University of Hong Kong, passive PH is due to high pressure in post-pulmonary capillaries, active PH is due to obstructions in capillary and precapillary vessels, and reactive PH is due somewhat to an active-superimposed-on-passive component.
  •   
  • Marathoner Tells How She Deals with Exercise-Induced PH, Advocates for Early Diagnosis
  • (Lung Disease News) Roseanne Huber was like any other 40-year-old woman that had decided to improve her quality of life getting in shape, when, after experiencing symptoms of shortness of breath and a misdiagnosis, the doctors told her she suffered from exercise-induced pulmonary hypertension (PH), an untreatable disease. Eight years later, she explained to the Pulmonary Hypertension Association (PHA) on their blog how they helped her manage the rare and debilitating disease, while not having to abandon her passion for exercise.
  •   
  • New Stem Cell Treatment for IPF
  • (Lung Disease News) Generation of iPSC Suggests New Idiopathic Pulmonary Fibrosis Stem Cell Treatment
    ...a team of researchers, Amiq Gazdhar and colleagues, sought to evaluate the potential of induced pluripotent stem cells (iPSC) conditioned media (iPSC-cm) to regenerate and repair the alveolar epithelium in vitro and improve bleomycin induced lung injury in vivo....
    The most common cause of death related to IPF is respiratory failure. Other causes of death include pulmonary hypertension, heart failure, pulmonary embolism, pneumonia, and lung cancer....recently, cell based approaches have been proposed as new possibilities to regenerate various organs, including the fibrotic lung.

    The generation of human induced pluripotent stem cells (iPSC) has opened up a new avenue for patient-specific cell based therapies.
    In this study, researchers showed that conditioned media obtained from iPSC improved alveolar epithelial repair in vitro and attenuated bleomycin induced lung injury and fibrosis in vivo
  •   

News Archives
Take the Current Poll
View Current Poll Results To Date
View the Poll Archives